Verrica Pharmaceuticals (VRCA) Shares Outstanding (2017 - 2026)
Verrica Pharmaceuticals (VRCA) posted quarterly Shares Outstanding (Entity) of $17.2 million for Q1 2026, up 87.05% year-over-year from $9.2 million in Q1 2025, and up 61.37% quarter-over-quarter from $10.7 million in Q4 2025.
Verrica Pharmaceuticals (VRCA) Shares Outstanding (2017 - 2026) Analysis & Trends
Verrica Pharmaceuticals' Shares Outstanding (Entity) history runs 10 years deep, the most recent figure standing at $17.2 million for Q1 2026.
- In Q1 2026, Shares Outstanding (Entity) rose 87.05% year-over-year to $17.2 million; the TTM figure through Mar 2026 stood at $17.2 million (up 87.05% YoY), while the FY2025 annual figure was $10.7 million, up 105.61% from the prior year.
- Shares Outstanding (Entity) for Q1 2026 stood at $17.2 million, up from $10.7 million in the prior quarter.
- The five-year high for Shares Outstanding (Entity) was $17.2 million in Q1 2026, with the low at $2.8 million in Q1 2022.
- The 5-year median for Shares Outstanding (Entity) is $4.3 million (2024), against an average of $6.1 million.
- The sharpest annual moves came in 2022 and 2025: Shares Outstanding (Entity) increased 0.02% in 2022, then jumped 117.69% in 2025.
- Verrica Pharmaceuticals' Shares Outstanding (Entity) stood at $3.4 million in 2022, then grew by 24.46% to $4.3 million in 2023, then climbed by 21.85% to $5.2 million in 2024, then surged by 105.61% to $10.7 million in 2025, then surged by 61.37% to $17.2 million in 2026.
- Business Quant data shows VRCA's Shares Outstanding (Entity) at $17.2 million in Q1 2026, $10.7 million in Q4 2025, and $9.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 133.61 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 241.70 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 217.35 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 445.06 Mn |
| 10 | Verrica Pharmaceuticals | 102.80 Mn | 91.60 Mn | - | 21.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 21.31 Mn |
| Mar 31, 2026 | 21.31 Mn |
| Dec 31, 2025 | 10.65 Mn |
| Sep 30, 2025 | 9.49 Mn |
| Jun 30, 2025 | 9.49 Mn |
| Mar 31, 2025 | 9.48 Mn |
| Dec 31, 2024 | 5.18 Mn |
| Sep 30, 2024 | 4.68 Mn |
| Jun 30, 2024 | 4.65 Mn |
| Mar 31, 2024 | 4.65 Mn |
| Dec 31, 2023 | 4.53 Mn |
| Sep 30, 2023 | 4.61 Mn |
| Jun 30, 2023 | 4.59 Mn |
| Mar 31, 2023 | 4.30 Mn |
| Dec 31, 2022 | 3.42 Mn |
| Sep 30, 2022 | 4.03 Mn |
| Jun 30, 2022 | 2.75 Mn |
| Mar 31, 2022 | 2.75 Mn |
| Dec 31, 2021 | 2.70 Mn |
| Sep 30, 2021 | 2.75 Mn |